Baxter International

Investigation Alert Acadia Healthcare, Virtu Financial, Baxter International, and Hawaiian Electric: Johnson Fistel, LLP Encourages Investors to Submit Their Information Below

Retrieved on: 
Thursday, March 28, 2024
Virtu Financial, Baxter International, Hawaiian Electric Industries, Risk, SAN, LLP, Virtu, Complaint, HE, Wildfire, Pharmaceutical industry

Johnson Fistel, LLP is investigating potential claims on behalf of Acadia Healthcare Company, Inc. (NASDAQ: ACHC) ("Acadia") against certain of its officers and directors.

Key Points: 
  • Johnson Fistel, LLP is investigating potential claims on behalf of Acadia Healthcare Company, Inc. (NASDAQ: ACHC) ("Acadia") against certain of its officers and directors.
  • If you have continuously owned Virtu Financial, Inc, shares since before March 1, 2019, submit your information below:
    Recently a class action lawsuit was filed against the company.
  • Johnson Fistel, LLP is investigating potential claims on behalf of Baxter International, Inc. (NYSE: BAX).
  • Johnson Fistel, LLP is investigating potential claims on behalf of Hawaiian Electric Industries, Inc. against certain of its officers and directors.

Clinical Communication & Collaboration Market Worth $4.8 billion | MarketsandMarkets™

Retrieved on: 
Tuesday, April 9, 2024
Hill-Rom, Microsoft, Patient, Conditional sentence, Trauma, TigerConnect, Big data, Investment, Patient safety, NEC, Jive Software, Automation, Partnership, Stryker Corporation, Software, Cisco, Baxter International, Safety, OPN, Privacy, Health, Advantage, Communication, Knowledge, Hospital, Research, Growth, Market development, UC, OCI, Operating, EHR, Physician, Nursing

Based on application, the Clinical Communication and Collaboration market is segmented into lab & radiology communication, nurse communication, patient communication & emergency alerts, physician communication.

Key Points: 
  • Based on application, the Clinical Communication and Collaboration market is segmented into lab & radiology communication, nurse communication, patient communication & emergency alerts, physician communication.
  • Moreover, the unique communication needs of physicians, including the requirement for secure and confidential communication channels, further highlights the importance of dedicated physician communication solutions within the clinical communication and collaboration market.
  • Clinical Communication & Collaboration Market Dynamics:
    Key Market Players of Clinical Communication & Collaboration Industry:
    Prominent players in the Clinical Communication and Collaboration market include Avaya LLC (US), Oracle (US), Cisco Systems, Inc. (US), Microsoft Corporation (US), Baxter International (Hillrom) (US), symplr (US), NEC Corporation (Japan), Spok Inc. (US), Vocera Communications (Stryker) (US), Ascom Holding AG (Switzerland), Everbridge (US), Hidden Brains InfoTech.
  • Market Diversification: Exhaustive information about the software portfolios, growing geographies, recent developments, investments in the Clinical Communication and Collaboration market.

Clinical Communication & Collaboration Market Worth $4.8 billion | MarketsandMarkets™

Retrieved on: 
Tuesday, April 9, 2024
Hill-Rom, Microsoft, Patient, Conditional sentence, Trauma, TigerConnect, Big data, Investment, Patient safety, NEC, Jive Software, Automation, Partnership, Stryker Corporation, Software, Cisco, Baxter International, Safety, OPN, Privacy, Health, Advantage, Communication, Knowledge, Hospital, Research, Growth, Market development, UC, OCI, Operating, EHR, Physician, Nursing

Based on application, the Clinical Communication and Collaboration market is segmented into lab & radiology communication, nurse communication, patient communication & emergency alerts, physician communication.

Key Points: 
  • Based on application, the Clinical Communication and Collaboration market is segmented into lab & radiology communication, nurse communication, patient communication & emergency alerts, physician communication.
  • Moreover, the unique communication needs of physicians, including the requirement for secure and confidential communication channels, further highlights the importance of dedicated physician communication solutions within the clinical communication and collaboration market.
  • Clinical Communication & Collaboration Market Dynamics:
    Key Market Players of Clinical Communication & Collaboration Industry:
    Prominent players in the Clinical Communication and Collaboration market include Avaya LLC (US), Oracle (US), Cisco Systems, Inc. (US), Microsoft Corporation (US), Baxter International (Hillrom) (US), symplr (US), NEC Corporation (Japan), Spok Inc. (US), Vocera Communications (Stryker) (US), Ascom Holding AG (Switzerland), Everbridge (US), Hidden Brains InfoTech.
  • Market Diversification: Exhaustive information about the software portfolios, growing geographies, recent developments, investments in the Clinical Communication and Collaboration market.

ProKidney Reports Full Year 2023 Financial Results and Recent Corporate Highlights

Retrieved on: 
Thursday, March 21, 2024
Research, Health, Commercialization, Transplant, CKD, Risk, Patient, AHN, Kidney failure, Biostatistics, CBO, Business development, Overalls, Quality of life, Trial of the century, Kidney disease, CVS Health, Clinical trial, EGFR, Chronic kidney disease, Dialysis, Baxter International, Type, Pharmaceutical industry

WINSTON-SALEM, N.C., March 21, 2024 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company"), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD), today announced financial results for the year ended December 31, 2023.

Key Points: 
  • WINSTON-SALEM, N.C., March 21, 2024 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company"), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD), today announced financial results for the year ended December 31, 2023.
  • In November, the Company announced Dr. Bruce Culleton assumed the role of the CEO and joined the ProKidney board of directors.
  • Dr. Culleton joined ProKidney in July 2023 as Executive Vice President of Clinical Development and Commercialization.
  • Mr. Periera-Kamath had previously joined ProKidney in July 2023 as Vice President of Business Development & Innovative Solutions.

Baxter Announces U.S. FDA Clearance of Novum IQ Large Volume Infusion Pump and Dose IQ Safety Software, Advancing Connected and Intelligent Infusion Therapy

Retrieved on: 
Monday, April 1, 2024
Technology, Medical Devices, Hospitals, FDA, Health Technology, Software, Biotechnology, General Health, Pharmaceutical, Health, SYR, Novum, LVP, EMR, Patient, State, Food and Drug Administration, CQI, Hospital, Pharmacist, Baxter International, Computer security, Safety, Nursing, Baxter, Medicine, Pump, Food, Medical device

Baxter International Inc. (NYSE:BAX), an innovative leader in infusion therapies and technologies, today announced U.S. Food and Drug Administration (FDA) 510(k) clearance of its Novum IQ large volume infusion pump (LVP) with Dose IQ Safety Software.

Key Points: 
  • Baxter International Inc. (NYSE:BAX), an innovative leader in infusion therapies and technologies, today announced U.S. Food and Drug Administration (FDA) 510(k) clearance of its Novum IQ large volume infusion pump (LVP) with Dose IQ Safety Software.
  • Offering the Novum IQ LVP in the U.S. demonstrates Baxter’s commitment to continued innovation in advancing infusion therapy.
  • “The Novum IQ platform represents a meaningful shift in how connected and intelligent infusion therapy can impact the way clinicians provide care.
  • IQ Enterprise Connectivity Suite, a scalable all-in-one server, integration engine and software application platform, designed to simplify infusion system connectivity for the Novum IQ Infusion Platform.

Baxter to Host Annual Meeting of Stockholders in Virtual Format

Retrieved on: 
Wednesday, March 27, 2024
Health Technology, Health, Medical Supplies, Online, Medtech, Central Time, Baxter International, Baxter, Annual general meeting, Holding company

Baxter International Inc. (NYSE:BAX), a global medtech leader, will host its Annual Meeting of Stockholders (the 2024 Annual Meeting) in a virtual format on Tuesday, May 7, 2024 at 9 a.m., Central Time, as disclosed in Baxter’s proxy statement for the 2024 Annual Meeting.

Key Points: 
  • Baxter International Inc. (NYSE:BAX), a global medtech leader, will host its Annual Meeting of Stockholders (the 2024 Annual Meeting) in a virtual format on Tuesday, May 7, 2024 at 9 a.m., Central Time, as disclosed in Baxter’s proxy statement for the 2024 Annual Meeting.
  • As always, whether or not a stockholder plans to attend the virtual 2024 Annual Meeting, all stockholders of record are encouraged to vote their shares prior to the 2024 Annual Meeting by one of the methods described in the proxy materials for the 2024 Annual Meeting.
  • A list of Baxter's stockholders of record will be available for examination by stockholders on the 2024 Annual Meeting website during the meeting.
  • Stockholders that have not voted their shares prior to the 2024 Annual Meeting will be able to vote their shares electronically at the 2024 Annual Meeting by clicking “Vote Here” on the meeting website.

Spectral Medical Announces Amendment and Extension of Exclusive Supply and Distribution Agreement With Baxter Healthcare Corporation

Retrieved on: 
Wednesday, February 21, 2024
Baxter International, PMX, Sepsis, Intensive care unit, Amend, Investment, FDA, TSX, U.S. FDA, Risk, Baxter, Patient, Septic shock, United, Partnership, Pharmaceutical industry

TORONTO, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, is pleased to announce an extension to its supply and distribution agreement (the “Amended Agreement”) with Baxter Healthcare Corporation, a subsidiary of Baxter International Inc. (“Baxter”) (NYSE: BAX), originally entered into in February 2020.

Key Points: 
  • TORONTO, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, is pleased to announce an extension to its supply and distribution agreement (the “Amended Agreement”) with Baxter Healthcare Corporation, a subsidiary of Baxter International Inc. (“Baxter”) (NYSE: BAX), originally entered into in February 2020.
  • Spectral is a Phase 3 company seeking U.S. FDA approval for its unique product for the treatment of patients with septic shock, Toraymyxin™ (“PMX”).
  • “Baxter’s continued commitment to Spectral as our exclusive supply and distribution partner being extended for a ten-year period upon U.S. FDA approval provides us with great confidence in our commercialization path,” said Chris Seto, CEO of Spectral Medical.
  • On February 15, 2024, Spectral announced that it had reached the 90-patient enrollment threshold and provided written notification to Baxter of this achievement.

Fijoya Raises 8.3M Seed Funding to Pioneer AI-Powered Platform for Employer-Sponsored Healthcare

Retrieved on: 
Thursday, March 7, 2024
Technology, Insurance, Human Resources, Other Technology, Health Technology, Professional Services, Health Insurance, Health, Data Management, Other Professional Services, Baxter International, Acquisition, Polans (western), CPO, GM, Mastercard, HR, Ecosystem, Fintech, Genomics, Health insurance

Fijoya, a highly personalized platform for employer-sponsored health and wellness services, announced today an $8.3M funding round led by the Venture-Creation fund of Team8.

Key Points: 
  • Fijoya, a highly personalized platform for employer-sponsored health and wellness services, announced today an $8.3M funding round led by the Venture-Creation fund of Team8.
  • Operating at the intersection of fintech and healthcare, Fijoya offers employers a simplified, convenient, and cost-efficient way to offer more flexible health benefits.
  • Given the breadth of employer-sponsored healthcare, Fijoya will initially focus on challenges in the $32 billion point solution vendor market.
  • “This funding will allow Fijoya to expand its platform offerings in pursuit of a broad vision to change the landscape of employer-sponsored healthcare.

Baxter to Present at Raymond James 45th Annual Institutional Investors Conference

Retrieved on: 
Thursday, February 29, 2024
Health Technology, Health, Medical Supplies, Medtech, Conference, Baxter International

Baxter International Inc. (NYSE:BAX), a global medtech leader, will present at the Raymond James 45th Annual Institutional Investors Conference on Monday, March 4, 2024.

Key Points: 
  • Baxter International Inc. (NYSE:BAX), a global medtech leader, will present at the Raymond James 45th Annual Institutional Investors Conference on Monday, March 4, 2024.
  • Joel Grade, Baxter’s chief financial officer, is scheduled to present at 4:00 p.m. Eastern Time.
  • The live webcast of Baxter’s presentation can be accessed at www.baxter.com and will be available for replay through Friday, May 31, 2024.

Spectral Medical Announces Major Milestone by Reaching Its Interim Enrollment Target of 90 Patients

Retrieved on: 
Thursday, February 15, 2024
Baxter International, PMX, Sepsis, Intensive care unit, Spectral, FDA, TSX, Baxter, Patient, Septic shock, Acceleration, United, Partnership, Pharmaceutical industry

TORONTO, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today announced a major milestone by reaching its Interim Enrollment target of patient 90 in its TIGRIS trial.

Key Points: 
  • TORONTO, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today announced a major milestone by reaching its Interim Enrollment target of patient 90 in its TIGRIS trial.
  • Under the terms of the Company’s Exclusive Distribution Agreement with Baxter International (“Baxter”) (NYSE:BAX), at Interim Enrollment, Baxter has the option to make a second milestone payment to Spectral to maintain its PMX exclusive distribution rights.
  • As such, Spectral has formally notified Baxter of reaching its Interim Enrollment target of 90 patients.
  • “Enrolling patient 90 represents a major milestone in many ways for Spectral as we continue to see acceleration across our Tigris trial sites and building confidence and momentum towards completing the trial,” said Chris Seto, CEO of Spectral Medical.